Undisclosed DUB inhibitor / AbbVie, Mission Therap - LARVOL DELTA

[VIRTUAL] An hiPSC based genetic screening system to model aggregation of tau protein allows the identification and validation of possible targets for Alzheimers Disease therapies (AAIC 2020) - "The DUB enzymes revealed in our phenotypic screen have been validated in confirmatory studies and have the potential to become novel targets for the treatment of AD. In collaboration with Mission Therapeutics we will develop selective, potent DUB inhibitors for preclinical target validation."

Alzheimer's Disease • CNS Disorders • Targeted Protein Degradation

Mission Therapeutics raises £12m and deepens Pfizer relationship (Cambridge Independent) - "Mission Therapeutics has raised $15m (£12m) in equity investment and expanded its relationship with Pfizer....Capital would support the development of its world-leading DUB platform, and growth in its pipeline of DUB inhibitor programmes....Mission and Pfizer Inc have expanded their relationship by entering into an evaluation and option agreement for DUB target validation....The new agreement will enable Pfizer to access specific DUB inhibitors from Mission’s platform....Pfizer will have the option to negotiate target exclusivity for each of the DUBs of interest, but the deal does not include any of Mission’s own lead DUB programs, such as USP30."

Financing • Licensing / partnership • CNS Disorders • Parkinson's Disease